Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary Rob Fuchs joins ViewRay as Chief Human Resources Officer
CLEVELAND , Nov. 21, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of Robert M. Fuchs as Chief Human Resources Officer effective October 22 , 2018.  Mr.
Toggle Summary ViewRay® to Present at 30th Annual Piper Jaffray Healthcare Conference
CLEVELAND , Nov. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare Conference in New York, NY . Event :       30 th Annual Piper Jaffray Healthcare Conference
Toggle Summary ViewRay Reports Third Quarter 2018 Results
CLEVELAND , Nov. 8, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced financial results for the third quarter ended September 30, 2018 . Third Quarter 2018 Highlights: Total revenue of $17.7 million, primarily from 3 revenue units.
Toggle Summary ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK
New agreement expands access to precision radiotherapy for people with cancer CLEVELAND , Oct. 29, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK , Spain and Australia , to introduce the first

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Financial Events
More events are coming soon.
Featured Items

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449

In Need of Customer Support? Contact

  Language Select